|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Human database analysis using the Cancer Genome Atlas indicated that TMEM54, CD74, and TRIB3 were significantly increased and that ATOH8 was decreased in hepatocellular carcinoma.
|
31215104 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We demonstrated that CAC1 is over-expressed in malignant tumors, and cellular CAC1 depletion resulted in cancer growth suppression.
|
22903020 |
2012 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
CAC1 is highly expressed in cancer tissues and cancer cell lines.
|
19829063 |
2009 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We evaluated if BCLP mRNA detection in the blood is useful in gynecologic malignancies.
|
11724320 |
2001 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Via a 14;18 chromosomal translocation, BCLP is overexpressed in most follicular lymphomas as well as some other non-Hodgkin's lymphomas, and it has also been documented in other nonlymphomatous malignancies.
|
7590697 |
1995 |
|
Cardiovascular Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Compared to CAC = 0, individuals with CAC 1-10 had an increased multivariable-adjusted risk of CVD death only under age 40.
|
31784032 |
2020 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
We noted a significantly increased risk of CHD [hazard ratio (HR): 2.6 (1.5-4.3)] and CVD [HR: 2.3 (1.8-2.9)] mortality per unit increase in In (CAC + 1).
|
31486775 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Cox models were used to obtain hazard ratios according to CAC category, or per 1 SD log2[CAC+1], adjusted for vascular risk factor, APOE-ε4, with or without exclusion of interim stroke or cardiovascular disease.
|
28465455 |
2017 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These results suggested that an increase in Tmem54 and Cd74 expression via DNA methylation reduction was involved in the tumor increase in the F2 male offspring by gestational arsenite exposure of F0 females.
|
31215104 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Human database analysis using the Cancer Genome Atlas indicated that TMEM54, CD74, and TRIB3 were significantly increased and that ATOH8 was decreased in hepatocellular carcinoma.
|
31215104 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that miR-199a-5p can regulate CAC1 and function as a tumor suppressor in colorectal cancer.
|
22903020 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
CAC1 is highly expressed in cancer tissues and cancer cell lines.
|
19829063 |
2009 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that BCLP might be associated with cell morphology and a regulation of growth pattern of tumor.
|
11394883 |
2001 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer.
|
31504073 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer.
|
31504073 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further identified CAC1, a cell cycle-related protein expressed in colorectal cancer, as a miR-199a-5p target.
|
22903020 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further identified CAC1, a cell cycle-related protein expressed in colorectal cancer, as a miR-199a-5p target.
|
22903020 |
2012 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We noted a significantly increased risk of CHD [hazard ratio (HR): 2.6 (1.5-4.3)] and CVD [HR: 2.3 (1.8-2.9)] mortality per unit increase in In (CAC + 1).
|
31486775 |
2019 |
|
Diabetes Mellitus
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Adjusted multivariable analysis, compared to CAC-0, HR for all-cause mortality associated with CAC 1-99, 100-299 and ≫300 were 1.74(95% CI 0.65, 4.63, P-0.20), 5.54(95% CI 2.16, 14.22, P ≪ 0.001) and 5.75(95% CI 2.30, 14.37, P ≪ 0.001) in females with DM respectively; in males with DM HR associated with CAC 1-99, 100-299 and ≫300 were 1.87(95% CI 0.95, 3.66, P-0.06), 2.15(95% CI 1.05, 4.38, P-0.035) and 2.60(95% CI 1.34, 5.0, P-0.004), respectively.
|
31278061 |
2019 |
|
Coronary Artery Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among evaluated risk factors, age [odds ratio (OR) 1.04, 95% confidence interval (CI) 1.02-1.07, <i>p</i><0.001], current smoking status (OR 3.12, 95% CI 1.82-5.34, <i>p</i><0.001), and CAC 1-9 (OR 1.80, 95% CI 1.08-3.00, <i>p</i>=0.024) were significantly associated with moderate CAD.
|
31250575 |
2019 |
|
Cleft Palate
|
0.010 |
Biomarker
|
disease |
BEFREE |
More than half (55%, n = 36) were isolated cleft palates, and 35% (n = 23) were BCLPs.
|
29437500 |
2018 |
|
Hypertensive disease
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Each 1-unit increase in ln(CAC+1) was independently associated with a 12% higher risk of hypertension (95% confidence interval [CI] 9% to 16%).
|
29174140 |
2018 |